ResultsIQ

ResultsIQ › Latest results › Gaudium IVF and Women Health Limited

Gaudium IVF and Women Health Limited Q4 FY26 results deck summary

NSE: GAUDIUMIVF · BSE: 544709

Results deck of 29 May 2026, summarised by AI from the filing.

Gaudium IVF reported Q4 FY26 standalone revenue ₹2,216.60 cr (+31.76% YoY) and FY26 consolidated revenue ₹10,435.70 cr (+47.56% YoY).

Key takeaways

  1. FY26 results Consolidated revenue ₹10,435.70 cr (FY25: ₹7,072.40 cr, +47.56%); PAT ₹2,448.85 cr (FY25: ₹1,917.73 cr, +27.69%).
  2. Margin change Consolidated EBITDA margin 36.13% (FY25: 40.48%, -435 bps); PAT margin 23.47% (FY25: 27.12%, -365 bps).
  3. Growth driver Consolidated revenue growth driven by higher patient volumes across mature hubs, supported by strong clinical outcomes.

Original filing on BSE

Gaudium IVF and Women Health Limited Q1 FY27 results

As filed: Revenue ₹19.4 cr, EBITDA ₹2.4 cr, PAT ₹1.8 cr, EBITDA margin 12.5%.

Not scored. Too small to score: quarter revenue ₹19.4 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹30.4 cr, EBITDA ₹12.2 cr, PAT ₹8.4 cr, EBITDA margin 40.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹30.4 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −7.0% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹24.5 cr, EBITDA ₹6.6 cr, PAT ₹3.6 cr, EBITDA margin 26.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹24.5 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +2.2% in 30 days (Nifty 500: +4.3%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gaudium IVF and Women Health Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.